Lisata Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

Lisata Therapeutics, Inc. announced that it has reached agreement with the European Medicines Agency on a Pediatric Investigation Plan for Lisata’s lead investigational product, certepetide in pancreatic cancer.